Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global pseudobulbar affect treatment market is expected to grow at a CAGR of 9.20% during the forecast period of 2024-2032, driven by the rising prevalence of neurological disorders.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Pseudobulbar affect is a neurological disorder that causes sudden outbursts of laughter or crying that are uncontrollable. This condition can either develop through a brain injury or an underlying neurological condition, such as amyotrophic lateral sclerosis. Although there is no guaranteed cure available for the condition, there are medications available that can help in managing it.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on treatment, the market can be segmented into medication and occupational therapy, among others. Based on the route of administration, it can be bifurcated into oral and parental, among others. Based on drug class, the market divisions include antidepressants and nuedexta, among others. Based on distribution channels, the market can be segmented into retail pharmacies, hospital pharmacies, and online, among others. The regional markets for the pseudobulbar affect treatment market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global pseudobulbar effect treatment market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.
The market for pseudobulbar affect treatment, based on product type, can be bifurcated into medication and occupational therapy, among others.
The medication segment is expected to hold a major share of the market owing to rising efforts and investments to develop new and improved medications. Although companies are trying to develop new treatment options, there is only one medication approved by the Food and Drug Administration known as Dextromethorphan hydrobromide and quinidine sulfate (Nuedexta), which is specifically developed for Pseudobulbar affect treatment (PBA).
Based on regional markets, the market divisions include North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
North America is expected to dominate the pseudobulbar affect treatment market due to the rising prevalence of neurological disorders. The market development is aided by the growing geriatric population in the region. Furthermore, growing healthcare expenditures and the presence of significant key competitors will drive the market's growth rate in this region even faster.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Avanir Pharmaceuticals, Inc., was founded in 1988 and the headquarter is located in California, United States. It is a pharmaceutical manufacturing company that operates in the field with an aim to deliver innovative medicines to patients with central nervous system disorders. The company is a subsidiary of Otsuka America, Inc. (OAI), which is a holding company established in the United States in 1989.
Pfizer Inc. is a pharmaceutical and biotechnology company, headquartered in New York City, United States. The company was established in 1849 and they were one of the leading figures engaged in the development of a vaccine for COVID-19. Since the beginning of its operations, the company has evolved their product portfolio to include multitudes of products like Comirnaty, Eliquis, Ibrance, Prevnar family, and Xeljanz.
Eli Lilly and Company. is a global pharmaceutical company, which was founded in 1876 and headquartered in Indianapolis, United States. The company’s speciality lies in pharmaceutical development, biotech, and biopharmaceuticals. They have expertise in disease areas, such as Alzheimer’s, cancer, diabetes, immunology, obesity, and pain.
Other market players include Arrow Pharmaceuticals and AbbVie Inc., among others.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment |
|
Breakup by Route of Administration |
|
Breakup by Drug Class |
|
Breakup by Distribution Channels |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is expected to grow at a CAGR of 9.20% during the forecast period of 2024-2032.
The market growth is driven by the growing prevalence of neurological diseases and increasing investment in research and development to develop an improved and effective treatment solution.
The multiple plans implemented by governments around the world to develop the healthcare infrastructure can be a major boon to the market.
The regional markets for pseudobulbar affect treatment include North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
The treatments available in the market include medication and occupational therapy, among others.
The different routes of application for treatment include oral and parental, among others.
The drug classes available in the market include antidepressants and nuedexta, among others.
The primary distribution channels for pseudobulbar affect treatments include retail pharmacies, hospital pharmacies, and online, among others.
The key players in the market include Avanir Pharmaceuticals, Inc., Pfizer Inc., Eli Lilly and Company, Arrow Pharmaceuticals, and AbbVie Inc., among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124